Defeating Biliary Tract Cancer with ARTEMIDE-Biliary01: A New Hope By Steve|2024-10-11T15:58:46+13:00July 2nd, 2024|Categories: All, Trials & Studies, Z-Legacy|Tags: ARTEMIDE-Biliary01, PD-1, PD-L1, Rilvegostomig, TIGIT| Read More 0
Progression Free Survival Increases regardless of PDL-1 Expressions By Steve|2024-10-11T16:12:23+13:00October 22nd, 2018|Categories: Archived, Z-Legacy|Tags: immunotherapy, PD-L1| Read More 0
Cholangiocarcinoma – Keytruda as a first line treatment option ? By Steve|2024-10-11T16:12:57+13:00September 26th, 2018|Categories: All, Immunotherapy, Z-Legacy|Tags: ALK, EGFR, Keytruda, MSI-H, PD-L1, USA| Read More 0
Simplifying Immunotherapy terminology By Steve|2024-10-11T16:12:57+13:00September 15th, 2018|Categories: Archived, Z-Legacy|Tags: dmmr, Education, How, immunotherapy, Keytruda, MSI-H, Opdivo, PD-1 Checkpoint inhibitors, PD-L1, Terminology| Read More 1
Vyriad Expands Phase 1 Trial to Test Voyager-V1 By Steve|2024-10-11T16:13:35+13:00July 28th, 2018|Categories: All, Clinical Trials, Immunotherapy, Media, Z-Legacy|Tags: Bavencio, Colorectal Cancer, PD-L1, virotherapy, Voyager-V1| Read More 0
Can Bile Duct Cancer’s follow the Melanoma lead By Steve|2024-10-11T16:16:00+13:00January 11th, 2018|Categories: All, Immunotherapy, Z-Legacy|Tags: immunotherapy, Keytruda, Melanoma, PD-L1, Pembrolizumab| Read More 0